An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022

Since the early 1980s, phosphodiesterase 4 (PDE4) has been an attractive target for the treatment of inflammation-based diseases. Several scientific advancements, by both academia and pharmaceutical companies, have enabled the identification of many synthetic ligands for this target, along with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Crocetti, Letizia, Floresta, Giuseppe, Cilibrizzi, Agostino, Giovannoni, Maria Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370432/
https://www.ncbi.nlm.nih.gov/pubmed/35956914
http://dx.doi.org/10.3390/molecules27154964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370432/
https://www.ncbi.nlm.nih.gov/pubmed/35956914
http://dx.doi.org/10.3390/molecules27154964

Ejemplares similares